20th November 2020 – Glycostem today announced the
Glycostem initiates phase I/IIa trial of oNKord® in patients with Acute Myeloid Leukemia
FDA grants Glycostem’s oNKord® Orphan Drug Designation for Multiple Myeloma
12th October 2020 - Glycostem announces it has received the FDA’s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord®.
Glycostem collaborates with LUMICKS
30th July, 2020 - Glycostem collaborates with LUMICKS to improve immunotherapeutic drug development. By quantifying binding strength between immune and cancer cells using the unique z-Movi® Cell Avidity Analyzer, Glycostem exploits the predictiveness of avidity in finding the best NK-cell population for cellular therapy.
Glycostem partners with Zelluna Immunotherapy
19th November, 2019 - Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for the treatment of multiple solid cancers, and Glycostem Therapeutics BV, a clinical stage and leading Natural Killer (NK) cell manufacturing company, today announce that they have entered into a de
Glycostem welcomes Dr Rizwan Romee as US based advisor
12th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK cell company,today announced to have welcomed Rizwan
Glycostem signs first commercial agreement for oNKord® and new CAR-NK co-development agreement
11th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK-cell company, today announced the signing of a two agreements wit
Glycostem successfully completes funding round
9th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK-cell company today announced that Korean investor, E&F Healthcare Holdings and existing investor LUPUS Ventures B.V
Glycostem raises €5 million for clinical trials
September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK-cell company, today announced they have been awarded a €5 million loan from RVO’s Innovation Credit budget for clinical trials
Glycostem received GMP license for oNKord®
25th June 2019 - Glycostem Therapeutics BV today announced they have received GMP license for Glycostem’s proprietary closed production system used to manufacture their lead product, oNKord®, an off-the-shelf,allogeneic Natural Killer(NK) cell therapy.